Natalia Olchanski

[CEVR @TuftsCEVR]

📰New CEVR publication:

In an analysis on Medicare beneficiaries with dementia, @NOlchanski et al found that Medicare expenditures were higher for Black and Hispanic individuals compared with whites.

Read more: https://t.co/19kDp283Kf

@PaigeLin_HEOR
@Yolanda_Y_Zhu
@a_hfillit

[Peter Neumann @PeterNeumann11]

Value estimation of the #Diabetes Prevention Program.

@TuftsCEVR’s @NOlchanski shows the importance of prioritizing by diabetes risk using real world (vs clinical trial-based) data. #SMDM2023. @Tufts_PACE @AmDiabetesAssn

[Natalia Olchanski @NOlchanski]

Ways to help Ukraine in the midst of new disaster. Please consider supporting the rescue and evacuation efforts

[Timothy Snyder @TimothyDSnyder]

0/10 After Russia's destruction of the dam at Nova Kakhovka, Ukrainians face a manmade calamity amidst the other horrors of Russia's invasion. Ukrainians are at work rescuing their fellow citizens from high waters, often braving Russian fire to do it. Here are ten ways to help.

[Natalia Olchanski @NOlchanski]

@jchambers241 @PSynnott29 @dollendorf I was gonna say that too 🤣

[Natalia Olchanski @NOlchanski]

@tara_lavelle @PSynnott29 You convinced me!

[Natalia Olchanski @NOlchanski]

@tara_lavelle Thanks for the shout-out!

[Patricia Synnott @PSynnott29]

1 in 5 cost-effectiveness analyses account for patient heterogeneity say @tara_lavelle Tara and co. used the @TuftsCEVR #CEARegistry to understand how this can affect decision making. SPOILER we are misallocating resources by making decisions based on averages #ISPORAnnual

[Natalia Olchanski @NOlchanski]

Exploring Seattle at #smdm22

[Peter Neumann @PeterNeumann11]

.@TuftsCEVR's fall outing today to Spectacle Island in Boston Harbor.

What a great team!

[CEVR @TuftsCEVR]

“I would suggest you explore because this is a big field with many different ways of looking at things…I think it's really good to talk to people with different backgrounds..”
@NOlchanski on her advice to new health economists
Read her interview here: https://t.co/0qxWXOAUv7

[CEVR @TuftsCEVR]

@NOlchanski on her work on #Alzheimers disease:
“What I find motivating is the idea that our research can lead to some kind of improvement in practice and to people actually getting better access to services.”
Check out her full interview here: https://t.co/0qxWXOAmFz

[CEVR @TuftsCEVR]

Just out: Exclusive interview with CEVR’s Research Assistant Professor Natalia Olchanski, PhD, MS. Learn more about @NOlchanski's work on #Alzheimers disease and uncertainty in HTA.
https://t.co/0qxWXOiLgZ

[CEVR @TuftsCEVR]

New @alzdemjournals paper by @NOlchanski et al on #Alzheimers treatment disparities calls for providers and policymakers to work to identify factors limiting timely diagnosis and treatment and develop strategies to overcome those barriers. https://t.co/hwQxgB90ah

[CEVR @TuftsCEVR]

New pub by @NOlchanski finds that initiation of #Alzheimers meds did not vary by ethnoracial group but Black patients had lower adherence than white patients. Medication non-adherence & discontinuation were substantial & may relate to cost & access to care https://t.co/hwQxgB8skJ

[CEVR @TuftsCEVR]

New @alzdemjournals: @NOlchanski et al find that Black patients had lower #Alzheimers medication adherence than white patients. Across racial/ethnic groups AD medication non-adherence & discontinuation were substantial & may relate to cost & access to care https://t.co/4X7462eqX9

[CEVR @TuftsCEVR]

New @amcporg pub by @NOlchanski @PaigeLin_HEOR @jcohen1964

When are #BreakthroughTherapies (BT) cost-eff?

Evidence from published CE studies suggests that @US_FDA BT designation may be associated with ⬆️ value for money compared to non-BT therapies

https://t.co/ouJ930ZLMi

[CEVR @TuftsCEVR]

Use of @US_FDA breakthrough designation (therapies that have big potential to ⬆️ health but their value for money is not fully understood) is growing.

When are #BreakthroughTherapies cost-eff?

New @amcporg pub by @NOlchanski @PaigeLin_HEOR @jcohen1964

https://t.co/ouJ930ZLMi

[CEVR @TuftsCEVR]

New @amcporg pub by @NOlchanski @PaigeLin_HEOR @jcohen1964

When are #BreakthroughTherapies (BT) cost-eff?

Using #CEARegistry we compared cost-effectiveness of BT to non-BT therapies & identified factors associated w/ BT therapy cost-effectiveness

https://t.co/ouJ930ZLMi

[CEVR @TuftsCEVR]

New @amcporg pub by @NOlchanski @PaigeLin_HEOR @jcohen1964

When are #BreakthroughTherapies (BT) cost-eff?

BT therapies had more favorable cost-eff ratios compared to non-BT therapies (median values $38k/QALY vs $50k/QALY respectively)

https://t.co/ouJ930ZLMi

[Karen Freund MD @KarenFreundMD]

Great to work with @PaigeLin_HEOR @NOlchanski and @CEVR team. Important to recognize the disparities in #dementia care in order to develop interventions.